Novo Nordisk CEO Sees Demand for Better Products

The transcript discusses the company's earnings, market reaction, and performance, highlighting a 4% growth in the first half of 2018. It addresses US pricing pressures, including comments from President Trump, and the impact on drug pricing and Medicare codes. The company emphasizes its innovation in diabetes drugs and market share growth, particularly in the US and internationally. The M&A strategy focuses on biopharma, with challenges due to high valuations and cash availability.

What factors contributed to the company's performance in the first half of 2018?

How does the pricing situation in the US affect the company's business?

What challenges does the company face in maintaining pricing and access for patients?

What are the expectations for the GP1 space in terms of growth?

What is the company's strategy regarding M&A in the biopharma business?